Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma

Melanoma Research

Volumn 19, Issue 1, 2009, Pages 17-23

  Hofmann, Maja A ^a,b   Gussmann, Felix ^a   Fritsche, Andreas ^a   Biesold, Susanne ^a   Schicke, Bernd ^b   Küchler, Ingeborg ^b   Voit, Christiane ^a   Trefzer, Uwe ^a  

^a Skin Cancer Centre   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Follow up; Melanoma; Melanoma inhibitory activity; Sensitivity; Serum markers; Specificity

Indexed keywords

MELANOMA INHIBITORY ACTIVITY SERUM MARKER; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THICKNESS; TUMOR VOLUME;

EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 59549104902     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831bc78c     Document Type: Article

References (26)

1. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, et al. Autocrine tumor-cell growth-inhibiting activities from human-malignant melanoma. Cancer Res 1989; 49:5358-5363.
2. Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R. MIA (melanoma inhibitory activity) biological functions and clinical relevance. Hautarzt 1998; 49:762-769.
3. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, Mia. Cancer Res 1994; 54:5695-5701.
4. Koehler MR, Bosserhoff AK, vonBeust G, Bauer A, Blesch A, Buettner R, et al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 1996; 35:265-267.
5. Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004; 17:318-325.
6. Poser I, Golob M, Weidner M, Buettner R, Bosserhoff AK. Down-regulation of COOH-terminal binding protein expression in malignant melanomas leads to induction of MIA expression. Cancer Res 2002; 62:5962-5966.
7. Bosserhoff AK, Kuster H, Hein R. Elevated MIA levels in the serum of pregnant women and of children. Clin Exp Dermatol 2004; 29:628-629.
8. Hofmann MA, Gabriel V, Milling A, Kiecker F, Sterry W, Trefzer U. High-dose platinum combination therapy in pretreated patients with disseminated melanoma. Chemotherapy 2007; 53:422-428.
9. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57:3149-3153.
10. Auge JM, Molina R, Filella X, Bosch E, Cao MG, Puig S, et al. S-100 beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 2005; 25:1779-1782.
11. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20:2203-2207.
12. Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000; 20:5059-5063.
13. Krahn G, Kaskel P, Sander S, Waizenhofer JPY, Wortmann S, Leiter U, et al. S100 beta is a more reliable tumor marker in peripheral flood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21:1311-1316.
14. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff AK. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumor Biol 2001; 22:54-58.
15. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, et al. S100 beta and MIA are not superior to LDH in discriminating progressive from nonprogressive AJCC stage IV melanoma disease. J Clin Oncol 1999; 17:1891-1896.
16. Matsushita Y, Hatta N, Wakamatsu K, Takehara K, Ito S, Takata M. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Melanoma Res 2002; 12:319-323.
17. Garbe C, Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 2003; 26:241-246.
18. Tas F, Yasasever V, Duranyildiz D, Camlica H, Ustuner Z, Aydiner A, et al. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol-Cancer Clin Trials 2004; 27: 225-228.
19. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, et al. Diagnostic value and prognostic significance of protein S-100 beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003; 97:1737-1745.
20. Klimek VM, Williams L, Chapman PB. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Cytokines Cell Mol Ther 2002; 7:71-74.
21. Garnier JP, Letellier S, Cassinat B, Lebbe C, Kerob D, Baccard M, et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 2007; 43:816-821.
22. Bosserhoff AK, Kondo S, Moser M, Dietz UH, Copeland NG, Gilbert DJ, et al. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dynam 1997; 208: 516-525.
23. Muller-Ladner U, Bosserhoff AK, Dreher K, Hein R, Neidhart M, Gay S, et al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology 1999; 38:148-154.
24. Neidhart M, Muller-Ladner U, Frey W, Bosserhoff AK, Colombani PC, Frey-Rindova P, et al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000; 8:222-229.
25. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheumat Dis Clin North Am 2007; 33:57-70.
26. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 2006; 12:4605-4613.